-
Product Insights
NewNet Present Value Model: Intellia Therapeutics Inc’s NTLA-2001
Empower your strategies with our Net Present Value Model: Intellia Therapeutics Inc's NTLA-2001 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Innovation Ranking
Innovation Ranking – Intellia Therapeutics Inc
Intellia Therapeutics Inc (Intellia Therapeutics) is a biotechnology company. The company developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. It develops in vivo programs for the treatment of liver diseases such as alpha-1 antitrypsin deficiency, and primary hyperoxaluria Type 1. Intellia Therapeutics also develops ex vivo programs such as hematopoietic stem cells (HSCs) and chimeric antigen receptor T cells (CAR-T cells). The company’s pipeline products include OTQ923 / HIX763, NTLA-5001. The company conducts genome...
-
Product Insights
NewHemophilia A (Factor VIII Deficiency) – Drugs In Development, 2024
Empower your strategies with our Hemophilia A (Factor VIII Deficiency) – Drugs In Development, 2024 report and make more profitable business decisions. Hemophilia A is an X-linked recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII), which may be inherited or arise from spontaneous mutation. Depending on the level of FVIII activity, patients with hemophilia may present with easy bruising, inadequate clotting of traumatic injury, or in the case of severe hemophilia, spontaneous hemorrhage. Symptoms may include bleeding...
-
Product Insights
NewHereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Drugs In Development, 2024
Empower your strategies with our Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Drugs In Development, 2024 report and make more profitable business decisions. Hereditary angioedema (HAE) is a rare inherited disease that causes considerable swelling in various body tissues, such as the abdomen or face. Symptoms include severe abdominal pain and cramping, dehydration, diarrhea and shock, hoarse voice, difficulty swallowing,and difficulty breathing. Treatment includes medications such as epinephrine, antihistamines, and corticosteroids. The Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH]...
-
Product Insights
NewAlpha-1 Antitrypsin Deficiency (A1AD) – Drugs In Development, 2024
Empower your strategies with our Alpha-1 Antitrypsin Deficiency (A1AD) – Drugs In Development, 2024 report and make more profitable business decisions. Alpha-antitrypsin deficiency is an inherited disease that occurs due to lack of alpha-1 antitrypsin (AAT), a protein that protects the lungs. Symptoms include shortness of breath and wheezing, lung infections, rapid heartbeat, weight loss and vision problems. Predisposing factors include smoking, exposure to dust, chemical fumes, and infections. The Alpha-1 Antitrypsin Deficiency (A1AD) drugs in development market research report provide...
-
Product Insights
NewHemophilia B (Factor IX Deficiency) – Drugs In Development, 2024
Empower your strategies with our Hemophilia B (Factor IX Deficiency) – Drugs In Development, 2024 report and make more profitable business decisions. Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include bleeding into joints and associated pain and swelling, bruising, excessive bleeding following circumcision, gastrointestinal tract and urinary tract hemorrhage, and nosebleeds. Treatment includes replacing the defective clotting factor. The Hemophilia B (Factor IX Deficiency) drugs in development market research report provide...
-
Product Insights
NewHodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Drugs In Development, 2024
Empower your strategies with our Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Drugs In Development, 2024 report and make more profitable business decisions. Hodgkin lymphoma is a cancer that starts in white blood cells called lymphocytes. Symptoms include painless swelling of the lymph nodes in the neck, armpits, or groin, fever and chills, night sweats, weight loss, loss of appetite, and itchy skin. Hodgkin lymphoma is most common among people ages 15 to 35 and 50 to 70. Past infections with the...
-
Product Insights
NewPlasma Cell Neoplasm – Drugs In Development, 2024
Empower your strategies with our Plasma Cell Neoplasm – Drugs In Development, 2024 report and make more profitable business decisions. Plasma Cell Neoplasm or plasma cell cancer is a group of diseases involving B-cells. These tumors are found in soft tissues that can be malignant or benign. Multiple Myeloma, lymphoplasmacytic lymphoma, plasmacytoma are the types of plasma cell cancers. Of all three multiple Myeloma is the most common and aggressive form. Age, chronic infection, exposure to radiation, hereditary factors, are some...
-
Product Insights
NewHyperoxaluria – Drugs In Development, 2024
Empower your strategies with our Hyperoxaluria – Drugs In Development, 2024 report and make more profitable business decisions. Hyperoxaluria, a rare condition, manifests with recurrent kidney and bladder stones, often progressing to life-threatening end-stage renal disease (ESRD). The condition arises from the overproduction of oxalate, leading to abnormally high levels in urine. Primary hyperoxaluria types 1, 2, and 3 are caused by mutations in the AGXT, GRHPR, and HOGA1 genes, respectively. These genes guide the production of enzymes crucial for breaking...